1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
1.4 Market by Type
1.4.1 Global Diabetic Nephropathy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ACE Inhibitors
1.4.3 ARBs
1.4.4 Diuretics
1.4.5 Calcium Channel Blockers(CCBs)
1.4.6 Renin Inhibitors
1.4.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.4.8 Antioxidant Inflammation Modulators(AIMs)
1.4.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.4.10 Endothelin-A Receptor(ETAR)Antagonist
1.4.11 G Protein-Coupled Receptors (GPCRs)
1.5 Market by Application
1.5.1 Global Diabetic Nephropathy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Diagnostic Labs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Nephropathy Market Perspective (2015-2026)
2.2 Global Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Nephropathy Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Nephropathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Diabetic Nephropathy Market Growth Strategy
2.3.6 Primary Interviews with Key Diabetic Nephropathy Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Market Size
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2015-2020)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Players (2015-2020)
3.1.3 Global Diabetic Nephropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Diabetic Nephropathy Market Concentration Ratio
3.2.1 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2019
3.3 Diabetic Nephropathy Key Players Head office and Area Served
3.4 Key Players Diabetic Nephropathy Product Solution and Service
3.5 Date of Enter into Diabetic Nephropathy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Diabetic Nephropathy Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Nephropathy Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Diabetic Nephropathy Market Size by Application (2015-2020)
5.2 Global Diabetic Nephropathy Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Diabetic Nephropathy Market Size (2015-2020)
6.2 Diabetic Nephropathy Key Players in North America (2019-2020)
6.3 North America Diabetic Nephropathy Market Size by Type (2015-2020)
6.4 North America Diabetic Nephropathy Market Size by Application (2015-2020)
7 Europe
7.1 Europe Diabetic Nephropathy Market Size (2015-2020)
7.2 Diabetic Nephropathy Key Players in Europe (2019-2020)
7.3 Europe Diabetic Nephropathy Market Size by Type (2015-2020)
7.4 Europe Diabetic Nephropathy Market Size by Application (2015-2020)
8 China
8.1 China Diabetic Nephropathy Market Size (2015-2020)
8.2 Diabetic Nephropathy Key Players in China (2019-2020)
8.3 China Diabetic Nephropathy Market Size by Type (2015-2020)
8.4 China Diabetic Nephropathy Market Size by Application (2015-2020)
9 Japan
9.1 Japan Diabetic Nephropathy Market Size (2015-2020)
9.2 Diabetic Nephropathy Key Players in Japan (2019-2020)
9.3 Japan Diabetic Nephropathy Market Size by Type (2015-2020)
9.4 Japan Diabetic Nephropathy Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Diabetic Nephropathy Market Size (2015-2020)
10.2 Diabetic Nephropathy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Diabetic Nephropathy Market Size by Type (2015-2020)
10.4 Southeast Asia Diabetic Nephropathy Market Size by Application (2015-2020)
11 India
11.1 India Diabetic Nephropathy Market Size (2015-2020)
11.2 Diabetic Nephropathy Key Players in India (2019-2020)
11.3 India Diabetic Nephropathy Market Size by Type (2015-2020)
11.4 India Diabetic Nephropathy Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Diabetic Nephropathy Market Size (2015-2020)
12.2 Diabetic Nephropathy Key Players in Central & South America (2019-2020)
12.3 Central & South America Diabetic Nephropathy Market Size by Type (2015-2020)
12.4 Central & South America Diabetic Nephropathy Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Diabetic Nephropathy Introduction
13.1.4 Novartis Revenue in Diabetic Nephropathy Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Diabetic Nephropathy Introduction
13.2.4 Merck Revenue in Diabetic Nephropathy Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Diabetic Nephropathy Introduction
13.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Abbott Laboratories
13.4.1 Abbott Laboratories Company Details
13.4.2 Abbott Laboratories Business Overview
13.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
13.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2015-2020)
13.4.5 Abbott Laboratories Recent Development
13.5 Sanofi
13.5.1 Sanofi Company Details
13.5.2 Sanofi Business Overview
13.5.3 Sanofi Diabetic Nephropathy Introduction
13.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2015-2020)
13.5.5 Sanofi Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Diabetic Nephropathy Introduction
13.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 AbbVie
13.7.1 AbbVie Company Details
13.7.2 AbbVie Business Overview
13.7.3 AbbVie Diabetic Nephropathy Introduction
13.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2015-2020)
13.7.5 AbbVie Recent Development
13.8 Reata Pharmaceuticals
13.8.1 Reata Pharmaceuticals Company Details
13.8.2 Reata Pharmaceuticals Business Overview
13.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
13.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2015-2020)
13.8.5 Reata Pharmaceuticals Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview
13.9.3 Bayer Diabetic Nephropathy Introduction
13.9.4 Bayer Revenue in Diabetic Nephropathy Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 Mitsubishi Tanabe Pharma
13.10.1 Mitsubishi Tanabe Pharma Company Details
13.10.2 Mitsubishi Tanabe Pharma Business Overview
13.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
13.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2015-2020)
13.10.5 Mitsubishi Tanabe Pharma Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer